Navigation Links
Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Date:4/4/2013

BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials.

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Results on the following trials presented at the meeting include:

ARRY-520 Single Agent Clinical Trial in Patients with Relapsed or Refractory Multiple Myeloma (MM) (Protocol # ARRAY-520-212)

  • ARRY-520 demonstrated single agent activity in heavily pretreated patients, with 19 months median Overall Survival and a 16% Overall Response Rate.  These results are similar to those for recently approved products Kyprolis® (carfilzomib) and Pomalyst® (pomalidomide) as single agents in a similar patient population.
  • ARRY-520 was generally well tolerated, with the predominant adverse events being transient and non-cumulative neutropenia and thrombocytopenia that were readily managed with growth factors and supportive care.
  • Consistent with other reported ARRY-520 study results, there was a low-incidence of non-hematologic adverse events with no treatment-related neuropathy observed.
  • Further data on a potential patient selection marker was also presented.  Patients with normal levels of alpha-1-acid glycoprotein (AAG) had a longer median Overall Survival (20.2 months vs 4.5 months), improved median Event Free Survival (5.3 months vs. 2.4 months) and greater Overall Response Rate (24% vs 0%) compared to patients with ele
    '/>"/>

  • SOURCE Array Biopharma
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
    2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
    3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
    4. Array BioPharma Announces Proposed Public Offering Of Common Stock
    5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
    6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
    7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
    8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
    9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
    10. Array BioPharma To Present At The Cowen Annual Health Care Conference
    11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
    (Date:7/31/2014)... 2014  Cepheid (NASDAQ: CPHD ) today announced ... and invited investors to participate via webcast. ... York, NY Wednesday, August 13, 2014 at 9.10 ... New York, NY Thursday, September 4, ... Live Webcasts To access the live webcasts for these events, ...
    (Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
    Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
    ... (Nasdaq: VRUS ) announced today the pricing ... its common stock at an offering price of $46.33 ... selling 2,300,000 shares and the selling stockholders are selling ... deducting the underwriting discount and estimated offering expenses, of ...
    ... investor meeting held today in New York, NY, Watson ... update on its Global businesses, including a detailed overview ... Global Generics and Global Brands businesses, and an update ... the meeting, the Company provided its preliminary 2011 financial ...
    Cached Medicine Technology:Pharmasset Prices Public Offering of Common Stock 2Pharmasset Prices Public Offering of Common Stock 3Watson Presents Outlook for Continued Long Term Growth 2Watson Presents Outlook for Continued Long Term Growth 3Watson Presents Outlook for Continued Long Term Growth 4Watson Presents Outlook for Continued Long Term Growth 5Watson Presents Outlook for Continued Long Term Growth 6Watson Presents Outlook for Continued Long Term Growth 7Watson Presents Outlook for Continued Long Term Growth 8
    (Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
    (Date:8/1/2014)... UK (PRWEB) August 01, 2014 ... Publications research reports have been added to its ... Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and ... The key pharma industry drivers include, among others, ... of personal hygiene. In 2015, the pharma market ...
    (Date:8/1/2014)... By Alan Mozes ... -- Across the country, barbershops serve as a time-honored destination ... want to see whether barbershops might also be the spot ... among black men. In a novel partnership, the U.S. ... State Department of Health (MSDH), enlisted the help of barbershop ...
    (Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... industry have benefited from innovative technologies that have ... resemble a patient's tooth color. Moreover, the burgeoning ... due to age-related tooth ailments. Due to long-term ... many elderly individuals have demanded dental fillings, veneers ...
    (Date:8/1/2014)... In today’s age, traditional learning methods ... individual. Hence, these methods need to be revamped, so ... be inculcated. In this age of the internet, online ... methods. Thus, learning management systems help in the planning, ... of now, these are proving to be very useful ...
    Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4
    ... prevent problems realted to the teeth. Kids who continue to suck ... may be more likely to end up// in the orthodontist's office ... study found that kids who used a pacifier or sucked their ... more likely to develop protruding front teeth and an irregular bite, ...
    ... sulfate to standard emergency department migraine therapy with ... effectiveness of treatment.// Dr. Jill Corbo, and colleagues ... the Bronx, New York, note that there is ... treatment of migraine headache and that studies in ...
    ... Dentists now have an easy painfree way to detect ... a technique which underwent clinical trials at the University ... be a significant advance over previous cytology (PAP smear-type) ... chairman or oral medicine early detection is our most ...
    ... have been drinking tap water contaminated with chemical byproducts ... water.// When it is added to water that contains ... however, it can form compounds such as chloroform that ... the Environmental Working Group and Public Interest Research Groups ...
    ... researchers at Hopkins University, they have found a way to ... immune system, surpassing an obstacle to certain forms of ... the body's immune response to developing cancer vaccines to reducing ... the core of the blood system.// They can give rise ...
    ... long-term intake of a diet high in retinol or vitamin ... vitamin or mineral taken in adequately is good for health. ... and ineffective.// We tend to think that vitamins are good ... when one component is taken in excess. The latest report ...
    Cached Medicine News:Health News:A new study surpasses Gene Therapy Hurdle 2
    Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
    Inquire...
    ... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
    Inquire...
    Medicine Products: